


High-fidelity Imaging Response Detection in Multiple Sclerosis

Dr Baris Kanber,
Translational Imaging Group,
Centre for Medical Image Computing,
Department of Medical Physics and Biomedical Engineering,
University College London

Background

- It is very important to be able to detect an imaging response to treatment in MS as imaging response often occurs before clinical response becomes material.
- However, bulk imaging measures such as the total lesion volume, the number of lesions, and brain parenchyma volume provide limited sensitivity for detecting an imaging response to treatment in MS.
 - i.e. they are too reductive.
- We hypothesised that automated, high-dimensional analysis of clinical MRI can sensitively capture the imaging effect of an intervention.



Approach

- Partition a collection of longitudinal scans in patients treated with natalizumab into sets that are either before or after the treatment boundary.
- Attempt to detect the treatment effect based on low- and high-dimensional models of trajectories of change.

Trajectories of Change

Treatment boundary


Scan 1



Scan 2



Scan 3



Total lesion volume	+ve	
Total brain volume	-ve	
Total brain disconnectome		+ve
Number of lesions	+ve	
.		
.		
High-dimensional versions of the above		

Scan 4



Scan 5




Total lesion volume	-ve	
Total brain volume	+ve	
Total brain disconnectome		-ve
Number of lesions	No change	
.		
.		
High-dimensional versions of the above		

Models

- Low dimensional:
 - Total lesion volume
 - Number of lesions
 - Total brain volume
 - Total brain disconnectome
 - Age and gender
- High dimensional:
 - Regional brain volumes
 - Regional brain disconnectome map
 - Best features from the above two

Brain Parcellation and Lesion Segmentation

T1-weighted structural scan



Brain Parcellation

*(Cardoso et al.,
IEEE Trans Med
Imaging, 2015)*

T2-FLAIR




Level 1
segmentation


*(Prados et al. ISBI
Longitudinal MS
Lesion
Segmentation
Challenge, 2015)*

Final segmentation


*(Sudre et al. IEEE
Trans Med Imaging,
2015)*



Disconnectome




Lesion mask



Tractography from healthy subjects

“Brain,
Connectivity,
Behaviour”
Toolkit



Disconnectome map

Tractography image from: <http://www.nrronline.org>


Inferential technique

- Classifiers:
 - Support vector machines (rbf kernel).
 - Extremely randomised decision trees (Tree-splitting metric: gini impurity).
- Bootstrapped cross-validation with fully held out test sets

Dataset

- 125 patients with remitting, relapsing MS
 - Data acquired over 15 years
 - 80 female, 45 male
 - Age at the start of treatment: mean: 38, range: 18-70
 - 166 pre-treatment, 413 post-treatment scans
 - T1-weighted structural, and T2-FLAIR scans included



Methods



- Adjusted for:
 - Age, gender, scanner manufacturer, field strength, T1 voxel size, FLAIR voxel size, disease duration, and EDSS.
 - ...using residuals from Bayesian Penalised Regression Estimation.

Figure above for the thalamus (right hemisphere) in a single patient.

Results




Fitted lines are obtained with Restricted Cubic Spline Regression

Total lesion volume

Pre-treatment


Post-treatment



Total brain disconnectome

Pre-treatment

Post-treatment




Group-level histograms of trajectories for the low-dimensional biomarkers.

Number of lesions

Pre-treatment


Post-treatment



Brain parenchyma volume


Pre-treatment

Post-treatment



High-dimensional biomarkers are the equivalents of these for the various regions of the brain as opposed to the brain as a whole.


Results



- Both the low and high-dimensional models could predict the imaging response to treatment: both ROC curves of both differed significantly from chance ($P < 0.01$ for both).
- However, there was also a significant statistical difference between the ROC curves of the high- and low-dimensional models ($P < 0.01$).
- The best high-dimensional model yielded a mean area under the ROC curve of 0.843 (95% CI: 0.835-0.851) which was significantly higher than 0.700 (95% CI: 0.691-0.709) obtained with the best low-dimensional model ($P < 0.01$).

** Two-sided, two-sample Kolmogorov-Smirnov tests.


Results



- Figure left:
 - Models are drawn in *blue* for the low-dimensional and *red* for the high-dimensional and are:
 - I (age and gender)
 - II (the number of lesions)
 - III (the total lesion volume)
 - IV (brain volume)
 - V (best low-dimensional)
 - VI (regional brain volume trajectories)
 - VII (regional disconnectome trajectories)
 - VIII (best high-dimensional).
 - Classifiers are: SVM (*unfilled bars*), and ERT (*filled bars*).


- Although the ERT classifier outperformed SVM for the best models, the superior performance of the high-dimensional models was consistent for both classifiers.

Results



- Performance of the best high-dimensional model surpassed that of the best low-dimensional model across the entire range.
 - Performance disparity increased with the number of patients.
 - No evidence that a plateau had been reached.
- Limited gains in increasing the number of subjects if you remain low-dimensional.

Results



- Relative predictivities of the disconnectome trajectories vs. relative predictivities of the volume trajectories for the brain regions most influential for imaging response detection.
 - Predictivities for each highly ranking brain region are in arbitrary units.
- The imaging features most relied upon by the best high-dimensional classifier were consistent with known patterns of lesion and parenchymal change in multiple sclerosis.

Conclusion

- Therapeutic effects can be sensitively detected by high-dimensional analysis of clinical neuroimaging.
- If it works for clinical imaging it is going to be even better for research imaging.
- We can monitor post-market much more sensitively than we currently do.

References

<u>Rojkova et al.</u>	<u>Atlasing the frontal lobe connections and their variability due to age and education: a spherical deconvolution tractography study.</u>	<u>Brain Struct Funct.</u>	2016	221(3)	1751-66
<u>Thiebaut de Schotten et al.</u>	<u>A lateralized brain network for visuospatial attention.</u>	<u>Nat Neurosci.</u>	2011	14(10)	1245-6
<u>Klein et al.</u>	<u>Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration.</u>	<u>Neuroimage</u>	2009	46(3)	786-802
<u>Avants et al.</u>	<u>A reproducible evaluation of ANTs similarity metric performance in brain image registration.</u>	<u>Neuroimage</u>	2011	54(3)	2033-44
<u>Wang et al.</u>	<u>Diffusion Toolkit: A Software Package for Diffusion Imaging Data Processing and Tractography</u>	<u>Proc. Intl. Soc. Mag. Reson. Med.</u>	2007		3720
<u>Thiebaut de Schotten et al.</u>	<u>Atlasing location, asymmetry and inter-subject variability of white matter tracts in the human brain with MR diffusion tractography.</u>	<u>Neuroimage</u>	2011	54(1)	49-59
<u>Thiebaut de Schotten et al.</u>	<u>From Phineas Gage and Monsieur Leborgne to H.M.: Revisiting Disconnection Syndromes.</u>	<u>Cereb Cortex</u>	2015	25(12)	4812-27
<u>Oliphant T.E.</u>	<u>A Bayesian perspective on estimating mean, variance, and standard-deviation from data</u>	<u>http://scholarsarchive.byu.edu/facpub/278</u>	2006		
<u>Geurts et al.</u>	<u>Extremely randomized trees</u>	<u>Mach Learn</u>	2006	63(1)	3-42
<u>Chang and Lin</u>	<u>LIBSVM : a library for support vector machines.</u>	<u>ACM Transactions on Intelligent Systems and Technology</u>	2011	2	1-27
<u>Pedregosa et al.</u>	<u>Scikit-learn: Machine Learning in Python</u>	<u>JMLR</u>	2011	12	2825-2830
<u>Modat et al.</u>	<u>Fast free-form deformation using graphics processing units</u>	<u>Computer methods and programs in biomedicine</u>	2009	98(3)	2009
<u>Kanber et al.</u>	<u>An integrated imaging informatics software platform to improve the analysis of clinical trials and research data in MS</u>	<u>ECTRIMS</u>	2016		